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Defining human cardiac transcription factor
hierarchies using integrated single-cell
heterogeneity analysis
Jared M. Churko1,2,3,4, Priyanka Garg1,2,3, Barbara Treutlein5, Meenakshi Venkatasubramanian6, Haodi Wu1,2,3,
Jaecheol Lee1,2,3, Quinton N. Wessells1,2,3, Shih-Yu Chen7, Wen-Yi Chen1,2,3, Kashish Chetal6, Gary Mantalas5,
Norma Neff5, Eric Jabart8,9, Arun Sharma 1,2,3, Garry P. Nolan7, Nathan Salomonis6 & Joseph C. Wu1,2,3
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have become
a powerful tool for human disease modeling and therapeutic testing. However, their use
remains limited by their immaturity and heterogeneity. To characterize the source of this
heterogeneity, we applied complementary single-cell RNA-seq and bulk RNA-seq technolo-
gies over time during hiPSC cardiac differentiation and in the adult heart. Using integrated
transcriptomic and splicing analysis, more than half a dozen distinct single-cell populations
were observed, several of which were coincident at a single time-point, day 30 of differ-
entiation. To dissect the role of distinct cardiac transcriptional regulators associated with
each cell population, we systematically tested the effect of a gain or loss of three tran-
scription factors (NR2F2, TBX5, and HEY2), using CRISPR genome editing and ChIP-seq,
in conjunction with patch clamp, calcium imaging, and CyTOF analysis. These targets, data,
and integrative genomics analysis methods provide a powerful platform for understanding
in vitro cellular heterogeneity.
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Heart tissue regeneration is a persistent challenge in thecardiovascular community. After a typical myocardialinfarction, it is estimated that over 1 billion cardiomyo-
cytes die1, leading to a drastic decline in heart function. Repla-
cement of an infarcted myocardium with cardiomyocytes
developed in vitro may be a viable solution. With continuing
improvements in developing efficient differentiation, large
quantities of highly purified populations of human embryonic
stem cell-derived cardiomyocytes (hESC-CMs) or human
induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) can now be obtained. However, these cardiomyocytes do
not match their mature in vivo derived counterpart2,3, as they
display differences in electrophysiological parameters4–6, con-
traction5,7, and gene expression profiles of nodal, atrial, and
ventricular cardiomyocytes8. Hence, characterization and
understanding of signaling pathways in cardiomyocyte develop-
ment must be further improved to realize the full potential of
hiPSC-CMs.
Modeling cardiovascular diseases, screening for drug toxicities,
and understanding heart developmental processes all require a
highly uniform population of cardiomyocytes. A complete tran-
scriptome analysis could provide pertinent information on the
maturation state of the cardiomyocytes, as well as which specific
population of cardiomyocytes is being assessed. A critical bot-
tleneck in understanding the whole transcriptome of hiPSCs is
the lack of reference gene expression signatures for hiPSC-CMs.
Differences in cardiomyocyte differentiation protocols, time
points analyzed, media compositions, or purity of cardiomyocytes
formed could all contribute to variable transcriptome inter-
pretations. In addition, profiling cardiomyocytes by RNA-seq or
microarray analysis on a bulk culture of cardiomyocytes (i.e.,
large cell numbers pooled together) only provides the average
gene expression and a collapsed view of the splicing events pre-
sent in cardiomyocytes. Recent analyses of single-cell cardiac
heterogeneity in embryonic hearts provide exciting insights
into a more complex mixture of cardiomyocyte populations
and transitioning transcriptional programs emerging throughout
development9,10. Similar analyses in human developing cardio-
myocytes that could be linked to distinct functional properties of
those cell states would shed significant light on the developmental
and functional properties of distinct cardiomyocyte populations.
Here we identified subpopulations of hiPSC-CMs represented
by distinct gene expression profiles through the extensive analysis
of multiple orthogonal single-cell and bulk RNA-seq datasets.
These cardiomyocyte populations were enriched for expression
of the transcription factors ISL1, NR2F2, TBX5, HEY2, or
HOPX. By combining RNA-seq, ChIP-seq, calcium imaging,
electrophysiological analysis, CyTOF, and RNA-seq of cardio-
myocytes deficient in three transcription factors, we were able
to derive an integrated transcriptional regulatory model that
implicates distinct hiPSC-CM states in cardiac maturation and
physiology. These data demonstrate that in using the small
molecule Wnt modulatory differentiation protocol, earlier hiPSC-
CMs exhibit more atrial-like gene expression profiles while pro-
longed culture produces more ventricular-like gene expression
and physiological signatures.
Results
Emerging cellular heterogeneity through differentiation. To
define multiple potential sources of cellular heterogeneity in
cardiomyocytes, we developed an integrated profiling strategy to
compare in vitro derived cardiomyocytes to in vivo adult analo-
gues, assessed their cellular and molecular heterogeneity, and
associated these cell states with specific transcriptional regulators
and physiological consequences (Fig. 1a). For these in vitro
studies, we utilized a popular cardiomyocyte differentiation pro-
tocol11 where a heterogeneous population of cardiomyocytes
(nodal-like, atrial-like, and ventricular-like) have been reported
(Fig. 1b)8. To broadly define the cellular heterogeneity arising
from this small molecule-based approach, we performed single-
cell RNA-seq on a total of 10,376 cells from two hiPSC lines at 0,
5, 14, and 45 days of cardiac differentiation using droplet-based
single cell sequencing (10X Chromium platform). Unsupervised
delineation of cell states using the recently described Iterative
Clustering and Guide-gene Selection (ICGS) algorithm identified
20 predominant cell states, containing distinct cardiac progenitor
and heart-associated cell populations (Fig. 1c)12. Seurat-CCA and
AltAnalyze also identified a number of distinct stem-progenitor
populations- pluripotent stem cells (PSC), definitive endoderm
(DE), mesoderm (MESO), ectoderm (ECTO), stromal, neural
crest (NC), endothelial, and early, mid or late cardiomyocyte
progenitors.
While this analysis identified multiple intriguing novel cell
states at each time point of differentiation that appear
transcriptionally distinct from cardiomyocytes, we chose to focus
further on the heterogeneity within the cardiomyocyte population
by isolating cardiac marker (TNNT2 and ACTC1) expressing cells
(4,689 cells) from day 14 and day 45 time points (Fig. 2a). A
focused analysis of these maturing cardiomyocyte populations
identified subpopulations of cardiomyocytes in early proliferative
stages (Cluster 4, 5), mid-cardiomyocyte stage (Cluster 2, 3), and
more mature stages (Cluster 0, 1) (Fig. 2b). Specifically,
comparing cardiomyocytes from day 14 to those from day 45
revealed that early stage cardiomyocytes were enriched for the
expression of VCAM1, APOE, NPPA, NPPB, MYH6, COL2A1,
HMGA1, S100A10, ATF4, RBFOX2, HMGA2, and CLDN6,
while the expression of HEY2, FHL2, CAV1, SERPINI1, MYL2,
A2M, LGALS3BP, TMEM173, SYNE2, NFIA, and HOPX were
enriched in day 45 cardiomyocytes. Hence, we find a continuum
of transitional transcriptomic hiPSC-CM gene expression states
associated with maturity over time in cell culture (Supplementary
Fig.1E).
Transcriptional regulators and cardiac heterogeneity. These
broad single-cell profiling analyses suggest that distinct matura-
tion and potentially physiological states underlie individual
intermediate time points of hiPSC-CM differentiation. Hence, to
determine if an intermediate time point of cardiac differentiation
would contain distinct combinations of these populations, we
next performed an independent single-cell RNA-seq analysis of
an intermediate CM differentiation time-point (day 30) using the
Fluidigm C1 system, which provides increased transcript coverage
and the sensitivity to potentially resolve specific splice isoforms
associated with cardiac maturity. Selecting 43 heavily sequenced
hiPSC-CMs (4 million paired-end reads) with cardiac specific
gene expression of cardiac troponin T Type 2 (TNNT2) and
cardiac alpha actin (ACTC1) (Supplementary Fig. 1A-D), we were
able to confirm the presence of distinct populations marked by
MYL2, MYH6, HOPX and other markers identified from droplet-
based sequencing analyses (see Materials and Methods). Unsu-
pervised ICGS analysis of these cells combined with supervised
analysis with guide-genes from Fig. 1b, we identified six distinct
cell populations defined by the expression of splicing factor 1
(SF1), ISL LIM Homeobox 1 (ISL1), Jumonji AT Rich Interactive
Domain 2 (JARID2), T-Box 5 (TBX5), Myosin Light Chain 2
(MYL2), or HOP Homeobox (HOPX) (Fig. 2c). While the tran-
scription factor Nuclear Receptor Subfamily 2 (NR2F2) was
highly expressed in the cell populations defined by ISL1, JARID2
and TBX5, MYL2 was expressed in a distinct subset of cells
overlapping with the Hes-Related Family bHLH Transcription
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Factor and YRPW Motif 2 (HEY2). ICGS clusters using 10X
single-cell RNA-seq from day 14 and day 45 cardiomyocytes also
revealed the expression of these transcription factors (pre-
dominantly HEY2 and MYL2 expression) in later stage (day 45)
cardiomyocytes compared to earlier time point cardiomyocytes
(day 14) (Supplementary Fig. 1E). Pseudotemporal ordering of
these cells with the software Monocle13 designated SF1-expres-
sing cardiomyocytes as the “earliest” population and HOPX as the
latest, suggesting that cardiomyocyte subpopulations underlie
distinct cardiac maturation states (Supplementary Fig. 1F). These
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results are in agreement with our broader single-cell analyses of
day 14 and 45 cardiomyocytes.
To determine if these transcription factors are likely to direct
the expression of the associated gene-expression clusters, we next
compiled gene expression signatures from several dozen tran-
scription factor perturbation transcriptome experiments (e.g.,
knock-out, siRNA, and over-expression) with available support-
ing ChIP-seq data (Supplementary Data 1). Among the 20
transcription factors evaluated, significant enrichment in
repressed HEY2 targets were found in ISL1-expressing cells,
whereas those repressed by NR2F2 were enriched in the
uncorrelated HEY2/MYL2 population. Similar analyses of a
dozen independent ontologies and curated gene sets found that
the NR2F2-expressing cells were most highly enriched in atrial
specific genes, whereas HEY2/MYL2 were most highly enriched in
ventricular morphogenesis genes (Fig. 2c, left panel). Hence, these
data suggest that cardiac differentiation is defined by distinct
transcriptional programs that can be associated with a more
immature/atrial-like gene expression profile that transitions into a
ventricular-like gene expression profile.
Single-cell populations correlate with time points. Based on our
bioinformatic predictions, we surmised that single-cell popula-
tions might underlie the cellular heterogeneity commonly
observed in previous cardiac differentiation studies4–6,14. To test
this hypothesis, we performed an in-depth bulk RNA-seq analysis
of 13 time points during cardiac differentiation of iPSCs, span-
ning days 0 through 90 of differentiation, with three replicate
differentiations (Supplementary Fig. 2A, Supplementary Data 2).
Genes defining each stage of differentiation from this time course
were obtained using the MarkerFinder algorithm within AltA-
nalyze, which selects genes with the greatest time point restricted
expression pattern, ordering the genes within each sample set
according to their relative specificity15. Gene Ontology enrich-
ment analysis of the MarkerFinder-defined gene sets correspond
to well-defined early mesoderm (day 1–3), cardiac progenitor
specification (day 4–6), cardiac structural maturation (day 7–9),
and contraction (day 14–90) markers. These expression changes
were further characterized by established marker genes in
mesoderm morphogenesis (T, MIXL1), early cardiac progenitors
(PDGFRA, MEF2C, BMP2, MKL2, PITX2, SNAI2, KDR, and
MYOCD), glycolysis (GPI, HK1, HK2, PFKP, and ENO1), sarco-
meric assembly (MYH6, CAPN3, NEB, EDN, and NKX2-5), and
cardiac contraction (MYL2, HCN4, CASQ2, GPD1L, JAK2, DES,
GJA5, PIK3R1, SCN5A, HEY2, FGF12, and DMD) (Supplemen-
tary Fig. 2A, right panel). While PCA analysis of each time point
of differentiation revealed a progression in gene expression sig-
natures from hiPSCs to cardiomyocytes, maintained in culture for
90 days, significant heterogeneity among similar time point
replicates were frequently observed (Supplementary Fig. 2B). To
test whether these in vitro maturity differences were a result of
underlying cell-state heterogeneity, we defined gene expression
centroids from our single-cell time-course data for ICGS cell
state-specific markers from MarkerFinder. Using the cell type
classification algorithm LineageProfiler12 in combination with
these marker gene profiles, we identified a gradual transition and
overlap between predicted pluripotent stem cell, endoderm,
mesoderm and cardiomyocyte subsets known to emerge at dif-
ferent time points from our droplet sequencing ICGS analysis
(Supplementary Fig. 2C). Importantly, this analysis underscores
the inherent differentiation-associated heterogeneity occurring
among replicates collected at the same time points, possessing
differential enrichment in early (day 5 and 14) versus late (day
90) in vitro progenitor populations. Hence, these results support
the hypothesis that differences in cell type composition underlie
the observed bulk gene expression changes observed in our time
course data.
In addition to these global observations, our bulk RNA-seq
time course data was used to evaluate the temporal specificity of
single-cell maturation state predicted markers. The expression of
NR2F2 and ISL1 is first observed at early differentiation time
points (day 3–4), TBX5 is expressed at intermediate time points
(day 5–14), and HEY2 and HOPX are expressed at late time
points of differentiation (day 9, 14, 30, and 90) (Supplementary
Fig. 2D). Examination of the predominant dynamically expressed
transcriptional regulators in this time course highlights both the
single cell population-specific genes along with established
regulators (Supplementary Fig. 3).
Global interactions of NR2F2, TBX5, and HEY2 populations.
Taken together, our single-cell gene and splicing analyses support
a model in which distinct cell populations associated with
opposing transcriptional regulators mediated cardiac maturation.
To understand the broader transcriptional regulatory network
associated with these population-specific factors, we next per-
formed ChIP-seq using previously validated antibodies for
NR2F2, TBX5, and HEY2. In all three ChIP-seq analyses, known
cis-regulatory binding sites (CisBP in HOMER) corresponding to
each respective transcription factor were enriched in proximity to
the transcriptional start sites (TSS) of target genes (Fig. 3a).
Pathway enrichment analysis of the associated ChIP-seq peaks16
identified an enrichment in neuronal encoding genes for NR2F2,
cardiac-specifying factors for TBX5, and neural-related and
enteric-related genes for HEY2 (Fig. 3b). Quantification of the
amount of nearest called genes to each ChIP-seq peak dataset
identified abundant genes called within the TBX5 dataset and
revealed a potential synergistic or antagonistic target regulation
with NR2F2 and HEY2 transcription factors (Fig. 3c). As pre-
dicted from our single-cell analysis, common ChIP-seq peak
regions were shared between different combinations of each
transcription factor and associated with the regulation of cardiac
differentiation-regulated genes, such as the ventricular marker
MYL2 (Fig. 3d).
To assess whether the identified ChIP-seq peaks could activate
or repress the nearest called target genes, we next sought to
identify how the transcriptome profile of cardiomyocytes changes
when the expression of NR2F2, TBX5, and HEY2 is perturbed. To
disrupt the function of each transcription factor, we used
clustered regularly-interspaced short palindromic repeats
(CRISPR) technology to delete exonic regions that are common
Fig. 1 Identification of hiPSC-CM subpopulations by single-cell RNA-seq. a Integrative analytical workflow for identifying distinct cellular populations from
single-cell RNA-seq analyses. Associated signatures can subsequently be further interrogated using orthogonal single-cell and bulk techniques (genome
editing, ChIP-seq targets, overexpression models, changes at the protein level) and functional assays (calcium handling, patch-clamp). b A monolayer
cardiomyocyte differentiation protocol was used to assess how single-cell populations change over time. Single-cell RNA-seq was performed on day 0, day
5, day 14, and day 45 of differentiation and 10,376 cell states identified using the software ICGS and Seurat-CCA. c A t-SNE plot was generated using
AltAnalyze to visualize the expression of ICGS associated markers during the different days of differentiation. Twenty distinct cell populations were
observed and could be attributed to populations representing pluripotent stem cells (PSC), definitive endoderm (DE), mesoderm (MESO), ectoderm
(ECTO), stromal, neural crest (NC), endothelial cells, and early, mid or late cardiomyocyte progenitors
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expressing HAND1, and more mature cardiomyocytes (Cluster 0, 1) expressing sarcomeric (MYH6, MYL2, TNNT2, MYBPC3) and calcium handling genes
(RYR2, PLN). c Single cells from day 30 of differentiation were profiled using an independent technology (Fluidigm C1) to resolve coincident mid-to-late
state differentiation heterogeneity. Genes associated with distinct observed cell populations identified by the algorithm MarkerFinder are shown. Factors
with defining expression in each of the HOPACH clustered populations are shown (SF1, ISL1, JARID2, TBX5, MYL2/HEY2, and HOPX). Two major groups in
hiPSC-CMs were observed to express either NR2F2 or MYL2/HEY2. Within each group, identified heart developmental regulators were identified using the
software GO-Elite (left panel)
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in multiple transcript variants from NR2F2, TBX5, or HEY2.
Using a guide RNA specific for NR2F2, we created an isogenic
hiPSC line harboring a large 89 bp deletion in exon 2 of NR2F2
from chr15:96334128-96334216 (NR2F2GE1). Using a guide RNA
specific for HEY2, we created an isogenic hiPSC line harboring a
15 bp deletion in exon 2 from chr6:125751839-125751854
(HEY2GE1). In addition, we included a hiPSC line previously
created by transcription activator-like effector nucleases (TALEN)
technology by our group which harbors a 29 bp deletion within
exon 2 of TBX5 from chr12:114403882-114403910 (TBX5GE1)17
(Supplementary Fig. 4A, B). Furthermore, to ensure all transcript
variants were impaired, we generated three lines harboring
additional large genomic deletions (whole exon deletions) by
using guide RNAs flanking exons within each transcription
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factor, annotated as GE2 (Supplementary Fig. 4C). The NR2F2GE2
line was a heterozygous deletion at chr15:96,880,430-96,881,090.
The TBX5GE2 line contained a homozygous 9.7 kb deletion at
chr12:114,823,085-114,832,791 and the HEY2GE2 line contained a
homozygous 371 bp deletion at chr6:126,075,494-126,075,865. To
assess the impact that disruption plays on each transcription
factor in cardiogenesis, we differentiated each line and performed
RNA-seq. The differentially expressed and opposing genes within
the NR2F2GE and HEY2GE lines corresponded to prior estab-
lished targets for both respective factors (Fisher-Exact enrichment
p < 0.01), validating the use of this approach (Supplementary
Fig. 4D)18,19.
To verify the role of each transcription factor in cardiomyo-
cytes, we next overexpressed NR2F2 (NR2F2OE), TBX5 (TBX5OE),
and HEY2 (HEY2OE) in day 30 hiPSC-CMs using lentivirus and
performed RNA-seq. To aid in the analyses of the associated
transcriptomic data, we compared the expression profiles of these
genes relative to control differentiations at the level of known
biological pathways and our single-cell informed population
subsets, combining RNA-seq from gene-edited lines for each
transcription factor (Fig. 3e, f). These analyses implicate distinct
transcriptional regulators in converging and/or opposing in vitro
maturation pathways. Specifically, NR2F2GE resulted in enhance-
ment of NUPR1 positive muscle-stromal-like cell associated genes
which emerged at 45 days of differentiation (Fig. 1b–d), whereas
HEY2GE or NR2F2OE blunted this cell-type specific signature, in
alignment with our predicted opposing role of these factors. In
addition, NR2F2OE resulted in an enrichment in pluripotent stem
cell (SOX2, POU5F1) and neuronal associated gene expression
(GPM6A, NEFM, NRCAM), while reducing expression of early
(COX6A2, SMTNL2) and late (MYH6, TNNI3) cardiomyocyte
associated genes. The predicted differentiation skewing observed
in NR2F2OE is consistent with this factor’s established role in
regulation of Notch signaling during differentiation20,21. Con-
sistent with our initial predictions, genes upregulated by HEY2GE
and downregulated by HEY2OE include NR2F2, the Notch
signaling genes (JAG1 and DLL3), regulators of cardiac
contractility (MYL3, COX6A1), neurogenesis (INA, BASP1,
NEFL), and human atria enriched genes (NR2F2, MYLK,
RBP1), while genes with the inverse signature included those
enriched in heart ventricles (PDLIM1, VTN, LPL) and cardiac
hypertrophy (MYH7, CORIN, TCAP). Surprisingly, genes dis-
playing reciprocal upregulation by NR2F2GE and downregulation
by NR2F2OE included TBX5 and atrial enriched genes (MYH6,
KCNK3, ACTA2) in addition to TGF-beta signaling (LEFTY2,
BMP4, GDF6, CDKN2B) and elastic fiber formation (MFAP2,
FBLN1, VTN), whereas the inverse pattern (in NR2F2OE)
included muscle relaxation (SLC8A1, CHGA, ATP2A2) and
neurogenesis (MYEF2, BMP2, NEFM) genes.
To further delineate how each transcription factor influences
the cardiomyocyte transcriptome, we next performed a joint
network analysis of our ChIP-seq and RNA-seq data. To visualize
this, we plotted each gene as a node and color coded the linked
interacting nodes using lines to demonstrate a repressive (red) or
active (green) interaction between each transcription factor and
the genes that were found to have changed (greater than 1.5-fold
change) within the gene edited lines (Fig. 3g). As previously
reported21-23, HEY2 interactions are predominately repressive
and TBX5 regulates a substantial number of cardiac genes. In
addition, we also identified multiple genes that were co-regulated
by NR2F2, TBX5, and HEY2, and plotted a select set of the cardiac
genes identified (Fig. 3h). Given that NR2F2 is expressed at an
earlier time point than TBX5 and HEY2, the later expression of
HEY2 and TBX5 likely contributes to the upregulation of gene
expression at later stages of differentiation. Specifically, later
expression of HEY2 and TBX5 was shown by ChIP-seq and RNA-
seq to positively regulate the expression of the ventricular marker
MYL2.
Ventricular and atrial marker expression in hiPSC-CMs. To
further assess how the atrial-like and ventricular-like identities
characterize hiPSC-CMs, we sought to analyze how genes enriched
in human adult atria versus ventricles change during hiPSC-CM
differentiation. We found that the expression of MYL2 (MLC2V) is
enriched within the right and left ventricle (RV, LV)22,23, whereas
MYL7 (MLC2A) is enriched within the right and left atrium (RA,
LA) (Supplementary Fig. 5A)24,25. Analysis of gene enrichment
over time revealed that ventricular markers (IRX4 and MYL2)
appeared only at later time points of differentiation (Supple-
mentary Fig. 2), MYL2 expression was highly correlated with the
HEY2-expressing subpopulation, and mRNA expression ofMYL2
was lower in TBX5GE and HEY2GE lines. Since ventricular mar-
kers could only be observed at later time points in differentiation,
we sought to determine how the atrial versus ventricular gene
expression signature develops over time.
As the complete RNA-seq transcriptome of normal (un-
diseased) human atria and ventricular heart tissue has not been
reported, we next performed RNA-seq on atrial and ventricular
tissue from a healthy heart that had been destined for a heart
transplant, but was rejected due to a donor mismatch. By plotting
the percentage of adult heart genes expressed within hiPSC-CMs
over time, we observed a progressive increase in the number of
Fig. 3 Transcriptome interactions between key transcription factors that regulate hiPSC-CM populations. ChIP-seq was performed on transcription factors
(NR2F2, TBX5, and HEY2) enriched within three hiPSC-CM populations. a ChIP-seq peak density demonstrates enrichment of the ChIP-seq signal around
the transcriptional start sites (TSS). b GO biological functions were graphed corresponding to peaks called within each ChIP-seq dataset (GREAT analysis,
hypergeometric test, p < 0.05). NR2F2 was highly enriched for terms within the nervous system, TBX5 for cardiac tissue, and HEY2 for neural and enteric
terms. c Venn diagram demonstrates the number of unique and common genes called (using HOMER) within each ChIP-seq dataset. d Coverage of the
reads demonstrating a peak near the MYL2 locus in the TBX5 and HEY2 ChIP-seq datasets, but not the NR2F2 dataset. e RNA-seq was performed on
cardiomyocytes from each gene-edited line [NR2F2GE (NR2F2GE1 and NR2F2GE2 lines), HEY2GE (HEY2GE1 and HEY2GE2), and TBX5GE (TBX5GE1 and
TBX5GE2)], as well as cardiomyocytes over expressing NR2F2 (NR2F2OE), TBX5 (TBX5OE) and HEY2 (HEY2OE). Biological terms associated with genes
significantly different (GO-Elite algorithm AltAnalyze) between these lines were annotated (left panel–blue text), as well as the corresponding ChIP-seq
peaks identified (right panel). Gene sets associated with each of the single-cell populations from Fig. 1b are highlighted in orange. Genes associated with
the enriched GO terms and single-cell populations are displayed to the right of the heatmap. f GO biological analysis was performed on significant genes
upregulated or downregulated in hiPSC-CMs overexpressing NR2F2, TBX5, or HEY2 with corresponding NR2F2, TBX5, or HEY2 gene-edited lines.
g Interactions among genes regulated by NR2F2, TBX5, and HEY2 were visualized by combining the significant genes called within each NR2F2GE1, TBX5GE1,
and HEY2GE1 with genes called within each ChIP-seq dataset. Nodes (blue circles) represent individual genes and the links represent the genes that interact
with each transcription factor. Red indicates an upregulation and green represents a downregulation observed in the RNA-seq of each gene-edited
line. h ChIP-seq/RNA-seq interactions using a selected set of cardiac-specific genes. MYL2 is highlighted to be positively regulated by TBX5 and HEY2
expression
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adult heart genes expressed during prolonged culture (Supple-
mentary Fig. 5B). To investigate whether ventricular markers are
enriched in cardiomyocytes at later time points, we assessed the
top 100 atrial and ventricular enriched genes (i.e., measuring the
greatest fold-change with empirical Bayes moderated unpaired t-
test assuming unequal variance with p < 0.05) (Supplementary
Fig. 5C) and graphed the percentage of atrial versus ventricular
enriched genes expressed throughout cardiac differentiation
(Supplementary Fig. 5D). At day 5 of differentiation, a similar
percentage of atrial-enriched and ventricular-enriched genes
could be detected. However, at day 6 in culture, a higher
percentage of ventricular enriched genes could be observed and
an increase in ventricular-enriched genes were detected through-
out differentiation.
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Given that our single-cell RNA-seq of the wildtype and
genome-edited lines suggested that NR2F2, TBX5, and HEY2 can
regulate atrial-like and ventricular-like signatures, we next
quantified the expression of these transcription factors within
the adult heart (Supplementary Fig. 5E). RNA-seq of the human
atria confirmed that NR2F2 and TBX5 are specifically enriched
within the atria, and HEY2 is highly enriched within the ventricle.
Similarly, immunofluorescent labeling of MLC2V and MLC2A
(Supplementary Fig. 5A) also verified differential expression of
these markers in the heart. RNA-seq quantification demonstrated
that MYL2 is highly expressed within ventricular tissue, while
MYL7 is enriched within atrial tissue (Supplementary Fig. 5F).
Furthermore, RNA-seq coverage of MYL2 and MYL7 in
differentiating hiPSC-CMs reveals that MYL2 is only observed
at later differentiation time points (e.g. day 30 and day 90)
(Supplementary Fig. 5G).
Single-cell protein quantification using CyTOF. Our tran-
scription factor interaction model revealed that late expression of
TBX5 and HEY2 regulate the mRNA level of MYL2. To validate
this finding at the protein level, we analyzed the expression of
MLC2V using time-of-flight mass cytometry (CyTOF) analysis
on a separate unbiased hESC line at three time points in differ-
entiation (day 8, day 18, and day 30) (Supplementary Fig. 6).
hESC-CMs (HES3 line) were stained with a panel of 37 elemental
isotope-conjugated antibodies and measured with mass cytometry
(Supplementary Fig. 6B). To visualize and interpret the high-
dimensional dataset generated, we applied the t-SNE algorithm
based on seven cardiac markers preselected for the dataset, in
which individual cells in the high-dimensional space were pro-
jected onto a two-dimensional map but their neighboring rela-
tionship was preserved. t-SNE segregated cells into spatially
distinct regions based on the markers expressed, and the relative
position of cells from each time point on t-SNE map strongly
correlated with the temporal order of differentiation (Supple-
mentary Fig. 6C). Similar to the mRNA expression of MYL2 and
MYL7 throughout cardiac differentiation, MLC2A was highly
expressed in the majority of cells at day 8, day 18, and day 30,
whereas the expression of MLC2V could only be observed at day
30 (Supplementary Fig. 6D). Interestingly, the match between the
continuum of marker expression and the established differentia-
tion status on t-SNE map similarly suggests the progression
MLC2A+ cells to MLC2V+ cells.
NR2F2, TBX5, and HEY2 regulate the cardiac action potential.
Pathway analysis performed using RNA-seq data from our gene-
edited lines revealed that genes involved in calcium signaling were
differentially expressed among the NR2F2GE, TBX5GE, and
HEY2GE lines. Given that NR2F2, TBX5, and HEY2 were differ-
entially expressed throughout different days in culture, we next
sought to determine how calcium signaling changes in control
hiPSC-CMs during prolonged culture (Fig. 4a). Calcium imaging
(using the calcium indicator dye Fura-2 AM) performed on day
14, day 30, and day 90 revealed a significant increase in baseline
ratio, peak ratio, amplitude, and maximum rising rate with a
decrease in transient duration over time. Next, we assessed
whether calcium signaling was affected in our day 30 NR2F2GE,
TBX5GE, and HEY2GE gene edited lines (GE represents data from
both GE1 and GE2 lines) (Fig. 4b). Interestingly, our ratiometric
calcium imaging with Fura-2 AM revealed a significant decrease
in the transient amplitude, immature calcium dynamics (shown
as decreased maximum rising/decay rate), and slower calcium
recycling rate (indicated by prolonged decay Tau) in TBX5GE and
HEY2GE lines when compared to control day 30 hiPSC-CMs. All
of these properties suggested that TBX5GE and HEY2GE lines had
a less mature phenotype. Finally, to determine whether NR2F2,
TBX5, and HEY2 are involved in the heterogeneous atrial- and
ventricular-like action potential as previously reported4–6, we
performed patch clamp analysis on control, NR2F2GE, TBX5GE,
and HEY2GE lines (Fig. 4c, d). Consistent with more immature
and atrial-like phenotype of cardiomyocytes, action potentials
within the HEY2GE group had a significantly more depolarized
minimum diastolic potential (MDP), lower upstroke velocity,
lower dv/dtmax, and lower action potential amplitude (APA)
compared to control cells (one-way ANOVA, p < 0.05). In addi-
tion, NR2F2GE hiPSC-CMs displayed significantly higher APD50
and APD90 values compared to control hiPSC-CMs. Differences
within AP parameters (ADP90, ADP50, and overshoot) therefore
suggest that action potential parameters are significantly influ-
enced by NR2F2 and HEY2. During days 30-40, the clear majority
(73%) of control, NR2F2GE, and TBX5GE hiPSC-CMs displayed
ventricular-like action potentials whereas the majority of HEY2GE
action potentials exhibited atrial-like action potential morphol-
ogy. These findings suggest that HEY2 is an important regulator
of the ventricular-like action potential identity (Fig. 4e).
Discussion
The heart has a limited regenerative capacity, and finding a sui-
table cardiomyocyte population to replace the cardiomyocytes
lost after injury would be extremely useful. Researchers now can
use hiPSC-CMs to repair the damaged heart, to model patient-
specific heart diseases, and to test drug responses; however, a
more thorough understanding of hiPSC-CMs is still needed.
Recent studies indicate that hiPSC-CMs represent a hetero-
geneous population displaying atrial-like, ventricular-like, or
nodal-like action potentials4–6, and numerous studies suggest that
these cells are immature relative to their adult counterparts3,26–28.
Given this reported heterogeneity, we sought to identify the
genetic signatures of these distinct populations, as well as provide
mechanistic insight into how each population arose. By using
single-cell RNA-seq, we identified subpopulations of cardio-
myocytes characterized by distinct underlying gene signatures,
Fig. 4 NR2F2, TBX5, and HEY2 influence the electrophysiological properties of hiPSC-CM lines. a Representative traces of calcium imaging on hiPSC-CMs
cultured for 14, 30, or 90 days in culture; over time, mature hiPSC-CMs presented a higher baseline ratio, peak ratio amplitude, maximum rising rate and
lower transient duration 50. b Calcium imaging was performed on control (day 30-40) and each gene-edited line (day 30–40) to assess the calcium
handling ability when NR2F2, TBX5, and HEY2 were disrupted. In comparison to control hiPSC-CMs, HEY2 lines displayed a significantly lower maximum
rising rate and amplitude. c Representative patch clamp electrophysiological recordings for each gene-edited line. d Action potential parameters for 22
control, 35 NR2F2GE, 36 TBX5GE, and 34 HEY2GE hiPSC-CMs at day 30-40 were quantified for either ventricular-like or atrial-like action potentials.
Significantly lower maximum rising rate (dv/dtmax), maximum diastolic potential (MDP), and action potential amplitude (APA) values were observed in the
HEY2GE line when compared to control lines. Increase in action potential amplitude (APD) 50 and APD90 was observed in the ventricular-like NR2F2GE
line. e The proportions of atrial-like, ventricular-like, and nodal-like action potentials were quantified within each gene-edited line. Slightly more ventricular-
like action potentials were found in the NR2F2GE line, whereas a large proportion of atrial-like action potentials were observed in the HEY2GE line. Lines
between bars represent p < 0.05 between groups using a one-way ANOVA
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subpopulation specific splicing events, and the enrichment of
specific cardiac transcription factors regulating these subpopula-
tions. Downstream analysis of three transcription factors revealed
that these subpopulations are related to different stages of cardiac
differentiation, as well as correlated with atrial-like or ventricular-
like gene signatures.
Single-cell RNA-seq on hiPSC-CMs from the same day after
differentiation (day 30) identified multiple subpopulations enri-
ched for TBX5, NR2F2, HEY2, ISL1, JARID2, or HOPX tran-
scription factors. By assessing the expression of these
transcription factors during differentiation, we observed that the
temporal expression pattern is correlated with unique sub-
populations. In conjunction with single-cell pseudotemporal
ordering and bulk RNA-seq comparison analyses, these data
suggest a model by which hiPSC-CMs from different days in
culture represent a pooled profile of cardiomyocytes from dif-
ferent differentiation stages and even distinct mesoderm-derived
cell populations. This is particularly evident in the cardiomyocyte
subpopulation expressing ISL1. Because ISL1 is a well-described
cardiomyocyte progenitor marker29,30, the temporal expression of
this transcription factor during cardiomyocyte differentiation
supports the idea that cardiomyocyte subpopulations represent
different stages of differentiation.
Our global single-cell analyses highlight transcriptional het-
erogeneity associated with reported atrial (NR2F2/TBX5) versus
ventricular (HEY2/MYL2) enriched gene expression change.
Given that an atrial enriched gene profile surfaces prior to the
expression of ventricular markers (IRX4 andMYL2), we surmised
that in using this small molecule differentiation protocol, ven-
tricular destined cardiomyocytes may progress from an imma-
ture/atrial-like (early stage) to a ventricular-like gene expression
profile. In this case, transcriptional regulators associated with
these distinct cardiomyocyte cell states would govern the switch
from an atrial- to ventricular-like state. Integrating our single-cell
RNA-seq results with patch clamp and gene expression profiling
of NR2F2 and HEY2 genome-edited lines, provides strong evi-
dence for the distinct regulatory role of NR2F2 versus HEY2 in
promoting atrial-like versus ventricular-like functional cell states,
respectively. The role that NR2F2 plays in regulating atrial
characteristics is supported by studies using retinoic acid to
increase the expression of NR2F2 and to generate atrial-like
hiPSC-CMs31,32.
The role that NR2F2 and HEY2 play in regulating an atrial-like
or ventricular-like gene expression profile has also been reported
in mice. By ablating Nr2f2 in the mouse myocardium, ven-
tricularization of the atrium was observed. In addition, ectopic
expression of Nr2f2 in the ventricle myocardium atrialized the
ventricular myocardium33. Hey2-deficient mice died within the
first week after birth due to cardiovascular defects (ventricular
septal defects, AV valve irregularities, and cardiac hypertrophy),
but mice defective in Hey genes produced ectopic activation of
atrial genes within the ventricular myocardium. Furthermore,
forced expression of Hey2 (Hrt2) in atrial cardiomyocytes was
found to suppress atrial specific genes. Here, we further show that
NR2F2 and HEY2 expression are mutually exclusive, with NR2F2
displaying robust expression in the human atrium and HEY2
in the human cardiac ventricle. Given that HEY2 belongs to the
notch signaling pathway and that significant regulation of key
Notch signaling proteins are found with the perturbations pre-
sented here, it is possible that notch signaling may be regulating
the atrial versus ventricular specific gene signatures within dif-
ferent heart chambers.
To model and understand cardiac disease, it is necessary to
identify the molecular and cellular sources of heterogeneity in
differentiating hiPSC-CMs. Here we combined our RNA-seq data
with transcription factor targeting analysis (ChIP-seq) to derive a
co-regulatory and counter-acting system of transcription factor
interactions centered on NR2F2, TBX5, and HEY2. Interestingly,
we observed common targets between these transcription factors,
suggesting the involvement of multiple transcription factors in
regulating the expression of cardiac genes. These data provide
strong complementary evidence that NR2F2 regulates genes
promoting an earlier atrial-like state, whereas the induction of
HEY2 promotes a more mature (i.e. later differentiation)
ventricular-like gene expression profile. This model is supported
by our RNA-seq data, which found genes enriched within the
adult cardiac ventricles (MYL2, NAV1, SLC5A1, ACTA1)
that were higher in the HEY2 overexpressing cardiomyocytes,
with subsequent decreased expression of these genes in HEY2
gene edited lines. Hence, aberrant signaling through transcription
factors enriched within a given heart chamber may be responsible
for regional pathology observed in some heart diseases. This
possibility is also supported by the positive correlation observed
between cardiac defects involved in Holt–Oram syndrome
(caused by TBX5 mutations) with the spatial expression of
Tbx534.
We believe that these analyses present a powerful strategy for
gaining novel integrated cellular, molecular and physiological
insights into differentiation-associated heterogeneity. This work
represents only the beginning of such investigations, given that
additional downstream studies will be needed to fully characterize
the several additional novel cell states found to emerge through
hiPSC-CM differentiation (Fig. 1b). Understanding which factors
regulate these cell fate decisions is likely to improve our ability to
generate enriched cardiomyocyte subtypes of differing maturity
and functionality. In the future, we believe that this type of
integrative single-cell analytical approach is likely to shed light on
additional complex cellular systems, beyond cardiac maturation.
Methods
Generation of human induced pluripotent stem cells. A skin punch biopsy was
performed and dermal fibroblasts were acquired from this biopsy under informed
consent as outlined in and approved by Stanford’s Institutional Review Board (IRB)
protocols. Fibroblasts were grown in DMEM supplemented with 10% fetal bovine
serum (FBS) and 1% pen/strep on gelatin-coated flasks. Fibroblasts were passaged
using trypsin and 1 × 106 fibroblasts were electroporated using 10 µg of repro-
gramming episomal vectors35 using the Neon® Transfection System. Fibroblasts
were plated onto Matrigel™-coated 10 cm culture wells in DMEM supplemented
with 10% FBS, 1% pen/strep, and hydrocortisone. Fibroblasts were then grown
using Essential 7 (E7) media [Essential 6 (Invitrogen) with FGF2 (50 µg/L)] and
sodium butyrate (0.2 mM NaB) (B5887 diluted in DMSO, Sigma) for thirteen days
and then switched to Essential 8 (E8) media (Invitrogen) until hiPSC colonies were
formed. hiPSC colonies were picked and expanded until passage 10 before being
used in experiments outlined below. hiPSCs were tested to be mycoplasma negative
using the Mycoalert Mycoplasma testing kits (LT07-318, Lonza).
Cardiomyocyte differentiation. Cardiomyocytes were differentiated using a
monolayer method as previously described11 with minor modification. hiPSCs
(passage 24-35) were seeded at 1.2 × 105 per well in Matrigel™-coated 6 cm culture
wells and grown for four days prior to starting hiPSC-CM differentiation. To
initiate differentiation, B27 without insulin (A1895601, Life Technologies) in RPMI
supplemented with 6 µM CHIR-99021 (CT99021, Selleckchem) was added to the
hiPSCs for two days. CHIR was removed from the cultures and cells were incu-
bated for one day in RPMI supplemented with B27 without insulin. Cultures were
then treated with 5 µM IWR-1 (I0161, Sigma) in RPMI supplemented with B27
without insulin for two days and incubated for two days with RPMI containing B27
without insulin. For two days, cultures were maintained in RPMI with B27 with
insulin (17504-044, Life Technologies) and glucose starved for three days (using
RPMI minus glucose). After glucose starvation, hiPSC-CMs were maintained in
RPMI with B27. Cardiomyocyte differentiation was repeated three additional times
and the cells were then processed for RNA-seq.
Overexpression of NR2F2, TBX5, and HEY2 in hiPSC-CMs. To overexpress
NR2F2, TBX5, and HEY2 in hiPSC-CMs, lentiviral particles were purchased for
mGFP-tagged NR2F2 (Cat# RC206753L2V), TBX5 (Cat# RC216520L2V), HEY2
(Cat# RC202544L2V), and control GFP Lent-ORF particles (Cat# PS100071V5)
from Origene. Two sets of day 30 hiPSC-CMs were infected with 1 or 2 MOI of
each lentivirus and maintained in culture for 1 week. RNA from NR2F2, TBX5,
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HEY2, and GFP infected hiPSC-CMs was extracted and RNA-sequenced using
Illumina’s HiSeq 4000 2 × 150 paired end sequencing (Novogene).
RNA-sequencing. RNA-seq of cardiomyocyte differentiation (N= 3 separate dif-
ferentiations) from hiPSCs was performed as follows: total RNA was isolated using
the miRNeasy Micro Kit (Qiagen). 100 ng of RNA was converted to cDNA using
the Ovation® RNA-Seq System V2 kit (NuGEN) as outlined in the manufacture’s
protocol. cDNA was fragmented using the Covaris S2 to an average fragment size
of 300 bp and the fragmented cDNA was purified using Agencourt AMPure XP
beads. End repair, dA tailing, and adapter ligation was performed using the
NEBNext DNA Library Prep Master Mix Set for Illumina (E6040L, NEB) with 500
ng sheared cDNA input. Size selection was performed on the Pippen Prep using 2%
DNA gels (12-100-506, Sage Science) to capture 300–360 bp DNA fragments. Bar-
coded RNA-seq libraries were pooled and hybridized to one lane of an Illumina
HiSeq 2000 flow cell using 2 × 100 paired end reads on the HiSeq 2000.
Two hiPSC lines were obtained from the Stanford Cardiovascular Institute
biobank (CVI0076, CVI0059). CVI0059 was processed for single cell RNA-seq at
day 5, day 14, and day 45 of the cardiomyocyte differentiation protocol using the
10X Genomics single-cell RNA-seq v1 kit. CVI0076 was processed for single cell
RNA-seq at day 0, day 5, day 14, and day 45 of the cardiomyocyte differentiation
protocol using the 10X Genomics single-cell RNA-seq kit v2. Single-cell RNA-seq
was performed as follows. Cells were trypsinized for 5 min and filtered through a
60 μm pore filter. Trypsin was removed by centrifugation and cells were washed
three times with PBS+ 0.04% BSA (Non Acetylated, Sigma B6917). Cells were
submitted to the Stanford Functional Genomics facility for single-cell library
preparation and sequencing. Briefly, Gel-Bead in Emulsions (GEMs) were
generated using the 10X Chromium system (10X Genomics, Pleasanton, CA).
Barcoded cDNA was extracted from the GEMs by Post-GEM RT-cleanup and
amplified for 12 cycles. Amplified cDNA was sheared (target –200 BP, Covaris S2),
and subjected to end-repair, poly A-tailing, adapter ligation, and 10X specific
sample indexing as per manufacturer’s protocol. Libraries were quantified using
Bioanalyzer (Agilent) and qPCR (KAPA) analysis. Libraries were sequenced on the
NextSeq 500 (Illumina). Unsupervised cell population discovery analyses were
performed with Seurat-CCA and the software ICGS available in AltAnalyze version
2.1.1 (http://www.altanalyze.org)12. For these analyses, only protein-coding genes
were considered, applying a correlation cutoff of 0.3 and Euclidean column
HOPACH clustering. Associated t-SNE visualizations were obtained in AltAnalyze
using ICGS obtained dynamically regulated genes.
Single-cell hiPSC-CMs (day 30 after differentiation began) were captured using
10–17 µM C1 Single-Cell Auto Prep IFC for mRNA-Seq (Cat# 5760, Fluidigm).
Single-cell RNA-seq libraries were further generated according to the
manufacturer’s protocol using the SMARTer Ultra Low RNA Kit for the Fluidigm
C1 (Clontech) and Nextera XT DNA Sample Preparation Kit (FC-131-1096,
Illumina). Each captured cell was labeled using a live and dead staining kit (L-3224,
Life technologies) and imaged using florescence microscopy in the capture site to
ensure viable, single cells were captured at each site and that these cells did not
represent doublets or dead cells. Cells were captured in 85 of the 96 capture sites,
19 of which were considered dead based on the florescent ratio of the dead versus
live stain and 15 sites with one or more cells observed (aka doublets, 18%). The
observed number of doublets for a single medium C1 chip is similar to the expected
rate suggested by the manufacturer (~30% with a standard deviation of 10%).
Doublets were defined as two or more cells that reside in either the wings of the
capture site or that are stacked on top of each other in the capture site nest, as per
the manufacturer recommendations. ERCC spike-ins were included for further
evaluation of sample quality. For the 51 libraries corresponding to single-live cells,
libraries were pooled and sequenced using Illumina’s HiSeq 2000 using 2 × 100
paired-end sequencing (Macrogen, South Korea). Filtered reads were aligned to the
reference genome hg19 using STAR36. Using STAR BAM files, AltAnalyze was
used to generate exon read counts for gene expression analysis and junction read
counts for splicing analysis (see below). All retained single-cell libraries were
required to have a minimum of 1 million uniquely aligning paired-end fragments
and > 40% aligned fragments, based on STAR analysis. The retained libraries had
an average of ~3 million aligned fragments. Analysis of these same libraries using
the Kallisto and TopHat2 workflows produced similar estimated and percentage
aligned fragment statistics37,38. This filtering excluded only two of the 51 libraries,
both of which had less than ~6,000 aligned fragments, with all retained cells having
over one million aligned reads. In addition, we applied a stringent filtering of the
cells based on the number of exon-exon junctions expressed ( > 400,000 junctions
reads/cell). To calculate RPKM values for each gene, AltAnalyze was run on the
junction and exon BED files using default settings. To identify discrete cell states,
unsupervised clustering was initially performed to define predominant populations
(ICGS module of AltAnalyze, Pearson correlation coefficient > 0.4). Although this
analysis identified three initial populations, we augmented these results using a
supervised analysis of cardiac transcription factors from our 10X Genomics
identified using the ICGS supervised correlation option. In agreement with our
Fluidigim C1 microscopy analyses, no gene expression signatures with evident
“doublet cell” profiles (more than one cell population signature) were discerned
from this analysis. Furthermore, ERCC spike-in expression (ERCC92.fa, Kallisto
TPM) ratios indicated single-cell transcriptome profiles were being assessed. Using
the obtained cell populations from this supervised analysis, the MarkerFinder
algorithm in AltAnalyze was run to identify additional genes with population-
restricted expression profiles (Pearson correlation coefficient > 0.4).
RNA-seq libraries for control, NR2F2GE1, and HEY2GE1 hiPSC-CMs were
created using the Ion AmpliSeq™ Transcriptome Human Gene Expression Kit (Life
Technologies). Each library was adjusted to a 100 pM concentration and Ion
Template preparation was performed using the automated Ion Chef system.
Templates were loaded on the Ion PI™ Chip Kit v3 (Life Technologies) and
sequencing was performed using the Ion Proton sequencing platform with the Ion
PI™ Hi-Q™ Sequencing 200 Kit (Life Technologies). Quantification of gene
expression differences was performed using the Ion Torrent Suite software (Life
Technologies) with the hg19_AmpliSeq_Transcriptome_21K_v1 reference.
Additional differentiations were performed on NR2F2GE1 (N= 2), TBX5GE1 (N=
2), HEY2GE1 (N= 2), NR2F2GE2 (N= 4), TBX5GE2 (N= 3), and HEY2GE2 (N= 2)
lines and sequenced using Illumina’s HiSeq 4000 2 × 150 paired end sequencing
(Novogene).
ChIP-sequencing. Cardiomyocytes (day 20 of culture, N= 1) were crosslinked by
1% formaldehyde and sheared using tip sonicator (450D, Branson). A small por-
tion of the crosslinked, sheared chromatin was saved as the input. Five micrograms
of either anti-NR2F2 (61213, Active Motif), anti-HEY2 (10597-1-AP, Proteintech)
or anti-TBX5 (SAB1411311, Sigma) was incubated with protein G Dynabeads
(10003D, Invitrogen) for 12 h at 4°C and the remainder were incubated with the
antibody conjugated Dynabeads. After overnight incubation at 4°C, the incubated
beads were rinsed with sonication buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1
mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5 mM PMSF),
high salt buffer (50 mM HEPES, pH 7.9, 500 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5 mM PMSF), and LiCl buffer (20 mM
Tris, pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 0.5
mM PMSF). The washed beads were incubated with elution buffer (50 mM Tris,
pH 8.0, 1 mM EDTA, 1% SDS, 50 mM NaHCO3) for 1 h at 65°C and then de-
crosslinked with 5M NaCl overnight at 65°C. The immunoprecipitated DNA was
treated with RNase A and Proteinase K, and purified by ChIP DNA clean and
concentrator (D5205, Zymo Research). 10 ng was used as input DNA into the
NEBNext® Ultra™ DNA Library Prep kit to add on sequencing adapters, and a
fragment size of 420–580 bp was isolated using the Pippen Prep (Sage Science).
Bowtie was used to map the raw sequencing reads to the reference hg19 genome
and peak calling was performed using MACS v2.0.1039. To annotate peaks to the
nearest transcriptional start site, Bedtools (Quinlan and Hall, 2010) and HOMER
(http://homer.salk.edu/homer/) were used. Peak bed files were also used as input
into GREAT to identify Biological Process Gene Ontology terms16. Lists of com-
mon ChIP-seq annotated genes and genes demonstrating a 2-fold change in
expression between control versus each gene-edited line (RNA-seq) were generated
to identify genes likely regulated by each transcription factor. Commonly called
genes between ChIP-seq datasets and RNA-seq datasets were merged to generate a
list of all transcription factor to gene interactions. Visualization of each interaction
between all genes (transcription factor interaction maps) was generated with a
modified code of the 3D Force layout using threejs (http://d3js.org/). Nodes
represented individual genes, the links represented an interaction between two
genes, and the color of the link indicated either an upregulation (green) or a
downregulation (red) observed in the RNA-seq datasets.
Gene editing cardiac transcription factors. TBX5 gene-edited line was previously
created and described17. Briefly, TALEN binding sites were designed using the TAL
Effector Nucleotide Targeter 2.0 having a repeat array length of 15 repeat variable
di-residue domains and a spacer length of 14–18 nucleotides40. TBX5 TALEN was
generated from a plasmid library through a five-piece subcloning ligation: three
sequence-specific tetramer-recognition pieces, one trimer-recognition piece, and an
expression vector backbone (pTAL) as previously described41. The forward con-
struct (containing the TBX5 start and reverse TALENs) were subcloned into the
pTAL_GFP and pTAL_RFP backbones. hiPSCs seeded at 2 × 106 cells were
transfected with a pair of TALENs (1.0 μg of each TALEN) by nucleofection using
the P3 Primary Cell Nucleofector Kit and program CM-150 per the manufacturer’s
instructions on the Amaxa 4D Nucleofector system (Lonza). Double GFP+ /RFP
+ cells were sorted by FACS (FACSAria II; BD Biosciences) and clonal selection
was performed as described below.
CRISPR guide RNAs were designed using the Zhang lab’s online CRISPR design
tool (http://crispr.mit.edu/). Guide regions were designed to represent exons shared
by multiple transcript variants of each gene (NR2F2 or HEY2) (Supplementary
Fig. 4). Guides were cloned into the pSpCas9(BB)-2A-GFP vector (gift from Feng
Zhang: #48138, Addgene) and 3 µg transfected into hiPSC cells using
Lipofectamine® 3000 reagent. Two days after transfection, GFP expression was
observed. GFP expressing hiPSCs were incubated for 5 min in Accutase to release
hiPSCs from the culture plate. hiPSCs were passed through a 100 µm cell strainer
and Accutase was removed by centrifugation at 300×g for 4 min. hiPSCs were
resuspended in 250 µL of FACS wash buffer (1% BSA in PBS) and FACS was then
performed using the FACSAria III cell sorter (BD Biosciences). Sorted cells were
seeded at a density of 1000 cells per well of a 6-well culture plate and were clonally
expanded for 7 days. To identify the genotype of each hiPSC clone, genomic DNA
was isolated from each CRISPR targeted clone using the DNeasy Blood & Tissue
Kit (Qiagen), and PCR was performed on the region spanning the CRISPR targeted
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site using PrimeSTAR® GXL DNA Polymerase (Clontech). Each PCR amplified
region was Sanger-sequenced (Quintara Biosciences, San Francisco) to validate the
targeted deletion. In addition, the PCR product was TOPO-cloned using a
StrataClone Blunt PCR Cloning Kit (Agilent), and plasmids from six clones (per
PCR product) was purified using QIAprep Spin Miniprep Kit (Qiagen) and
sequenced using the T3 primer (Quintara Biosciences). Sequencing each clone
identified a large 89 bp deletion in exon 2 of NR2F2 from chr15:96334128-
96334216 (NR2F2GE), as well as a 15 bp deletion in exon 2 of HEY2 from
chr6:125751839-125751854 (HEY2GE) (Supplementary Fig. 4B). NR2F2GE2,
TBX5GE2, and HEY2GE2 lines were created using the background corresponding
NR2F2GE1, TBX5GE1, and HEY2GE1 cell lines. Two CRISPR guide-RNAs targeting
sequences upstream of each exon (NR2F2: CAAACTGCCCCAACCGGAGT and
ATTTGCTCCAACTCCGGTTG, TBX5: GTTGGCGCCATTGGGCAACC and
TCACATGTGGTTGGCGCCAT, HEY2: AGTTGGGATTGTCTAGTGAG and
GTTGGGATTGTCTAGTGAGA), as well as two guide-RNAs targeting sequences
downstream of each exon (NR2F2: CAAGTTGTTCTGACCGACAC and AGCTA
GAGGTACATAGACAC, TBX5: CAAGGCGAATTTAGAGGGCG and GCGGG
GAGCAGGGTTTTATC, HEY2: AATGGCAGGATTGAACTCGT and TAATGG
CAGGATTGAACTCG) were used to create large deletions within each transcr-
iption factor using the same protocol outlined above. Clones were picked, and
sequence verified to reveal successful excision of each exon. PCR was also used to
verify deletions (using the primers: NR2F2: NR2F2-FGATCGTGGACGCCATTAC
NR2F2-R GTGCGTTTCCATCATCTTTG, TBX5: TBX5-F TTAGCACCAGCTTC
CAATC TBX5-R GTTCTCTCTTCCTCTTTCCTTC, HEY2: HEY2-F TTTGCTGT
GGTGATCTTAGG HEY2-R ATTACCTCTAACCTCCTGTTTATG) within each
region targeted (Supplementary Fig. 4C).
Immunocytochemistry and immunohistochemistry. Human heart atrial and
ventricular tissue was acquired under Stanford IRB approval. A 0.5 cm2 piece of
heart tissue was placed in 3.8% formalin for 5 h. After 5 h, samples were stored at 4°
C in PBS and submitted to the Department of Comparative Medicine’s Histology
Lab for paraffin embedding and tissue sectioning. 10 µM sections were fluores-
cently labeled as previously described42 using the antibodies ATTO® 550 con-
jugated anti-MLC2V (1:200, MYL2: 310-111AT2, Synaptic Systems) and ATTO®
647 N conjugated anti-MLC2A (1:200, MYL7: 310-011AT1, Synaptic Systems).
Sections were also stained using DAPI (1:1000) and imaged using a confocal
microscope (Zeiss LSM-510) in the Neuroscience Microscopy Service Facility
(Stanford University).
hiPSC-CMs were trypsinized after cardiac differentiation (day 9) and seeded
onto Matrigel®-coated 35 mm coverslips. hiPSC-CMs were maintained in RMPI/
B27 media until day 14, day 30, or day 90 after differentiation and fixed using ice-
cold 80% methanol/20% acetone at 4 °C for 20 min. Cells were rinsed with PBS for
5 min (repeated three times) and blocked using 3% Bovine Serum Albumin (BSA;
BP1600-100, Fischer BioReagents). Cells were labeled with the same antibodies and
concentrations used to label from the heart tissue immunohistochemistry section
above.
Single-cell CyTOF analysis of hESC-CM differentiation. Human ESC-CMs
(HES3, WiCell)43 were collected at the indicated time points, labeled with IdU to
assess cell proliferation, and with cisplatin for live–dead cell discrimination as
previously described44,45 (Supplementary Fig. 5A). Cells were then treated with 1 ×
TrypLE (Invitrogen) for 4 min at 37°C, dissociated into single-cell suspension by
trituration, filtered through a 40 um filter and fixed with 1.6% paraformaldehyde at
room temperature for 10 min followed by two washes with Cell Staining Medium
(CSM, PBS containing 0.5% BSA). Formaldehyde-fixed cell samples from different
time points were individually mass tag barcoded as previously described46. Indi-
vidual samples were then pooled and incubated with metal-conjugated antibodies
against surface markers for 1 h, washed once with CSM, permeabilized with
methanol on ice for 15 min, washed twice with CSM and then incubated with
metal-conjugated antibodies against intracellular molecules for 1 h. Cells were
washed once with CSM, and incubated at room temperature for 20 min with an
iridium-containing DNA intercalator (Fluidigm) in PBS containing 1.6% paraf-
ormaldehyde. After intercalation/fixation, the cell samples were washed once with
CSM and twice with water before measurement on a CyTOF mass cytometer
(Fluidigm). Normalization for detector sensitivity was performed as previously
described47. After measurement and normalization, the individual FCS files were
analyzed by first gating out doublets, debris and dead cells based on cell length,
DNA content, and cisplatin staining. viSNE maps were generated with software
tools available at www.cytobank.org using the indicated markers to perform
clustering48.
Ratiometric Ca2+ transient imaging. Differentiated beating hiPSC-CMs were
dissociated by Accutase and replated in Matrigel (BD Bioscience) pre-coated 25
mm round cover glass (Warner Scientific Inc.). Cells were recovered for 3-4 days.
For Fura-2 AM imaging, cells were loaded with 10 µM Fura-2 AM (stock solution
of Fura-2 AM was pre-dissolved in 20% Pluronic F-127 solution in DMSO) in
Tyrode’s solution (140 mM NaCl, 1 mM MgCl2, 5.4 mM KCl, 1.8 mM CaCl2, 10
mM glucose, and 10 mM Hepes pH= 7.4 with NaOH at RT) for 30 min at room
temperature. To pace cells, we used a custom-made LabView script to generate
pulse waveforms with a stimulus isolation unit (Warner Scientific Inc. SIU-102)
that generates pulse signals to stimulate hiPSC-CMs in the imaging chamber
(Warner Scientific Inc. RC-21BRFS). Cell samples were activated with Lamda-4
light source (Sutter) with fast switching between 340 and 380 nm wavelength, and
the emission signals were recorded with high-frame rate EMCCD (Andor iXon
Ultra897) that was connected to a reverse fluorescence microscope (Nikon. Ti-S)
with a 40X oil immersed objective (CFI Plan Fluor 40 × , NA 0.75). Signaling was
captured in fast frame rate video mode (512 × 512 frame) at a speed of 50 fps. For
data analysis, a custom-made script with Mat-lab was used. Transient amplitude
was expressed as R340/R380.
Electrophysiological recordings. The whole-cell patch clamp recordings were
performed using the standard patch clamp technique as previously described14.
Briefly, contracting monolayers of control and knockouts of NR2F2, HEY2, and
TBX5 hiPSC-CMs from days 30–40 were enzymatically dispersed into single cells
using Accutase, and attached to Matrigel-coated glass coverslips (Warner Instru-
ments) in RPMI medium supplemented with B27. After 72 h of incubation, action
potentials were recorded from single cells in the current clamp mode at 36–37 °C,
using an EPC-10 patch-clamp amplifier (HEKA, Lambrecht, Germany) attached to
a RC-26C recording chamber (Warner Instruments) and mounted onto the stage
of an inverted microscope (Nikon, Tokyo, Japan). The single cells were paced at
constant pacing rate of 1 Hz using a 5–20 ms depolarizing current injections of
150–550 pA. The glass pipettes were fabricated from standard wall borosilicate
glass capillary tubes (BF 100-50-10, Sutter Instruments) using a P-97 Sutter
micropipette puller, and fire polished with a microforge (Narishige, MF830, Japan)
to generate electrodes with tip resistances from 2-4 MΩ. Attached cells on cov-
erslips were continuously perfused with the extracellular solution containing (in
mM) 150 NaC1, 5.4 KCl, 1.8 CaCl2, 1.0 MgCl2, 15 HEPES, 15 glucose, and
1 sodium pyruvate (pH adjusted to 7.4 with NaOH). The intracellular solution
contained (in mM): 120 KCl, 1 MgCl2, 10 HEPES, 3 Mg-ATP, and 10 EGTA (pH
adjusted to 7.2 with KOH). Data were acquired using PatchMaster software
(HEKA), digitized at 1.0 kHz, and analyzed using FitMaster (HEKA, Germany),
Igor Pro (Wave Metrics) and Origin 2016 (OriginLab, Northampton, MA). All data
were expressed as mean ± S.E.M., and statistical significance was determined using
one-way ANOVA, with the significance level set at P < 0.05. We used the APD90/
APD50 ratio, which describes the shape of the repolarization curve, to determine
the specific subtype of each hiPSC-CM49. hiPSC-CMs with low APD90/APD50
ratios ( < 1.4, indicative of a pronounced plateau phase) were classified as ven-
tricular-like, whereas those with high APD90/APD50 ratios ( > 1.7, indicative of fast
phase-I repolarization) were classified as atrial-like. Cardiomyocytes with AP
characteristics intermediate between those of the atrial-like and ventricular-like
cells, with APD90/APD50 ratios between 1.4 and 1.7 were classified as nodal-
like14,49–53. In addition to the above criteria, to categorize hiPSC-CMs into each
subtype, action potential morphology was also considered. For example, action
potential morphology/phenotype with a negative diastolic membrane potential, a
rapid AP upstroke, and a long plateau phase was characteristic of ventricular-like
APs. The absence of a prominent plateau phase was a characteristic of atrial-like
APs, resulting in shorter AP duration compared to ventricular-like AP. Nodal-like
APs showed a more positive MDP, a slower AP upstroke, and a prominent phase 4
depolarization54.
Data availability
All relevant data is available from the authors. Sequencing data are deposited under
the Gene Expression Omnibus (GEO) accession number GSE81585. 10x Genomics
sequencing is deposited under synapse ID: syn7818379.
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